KD Logo

Amphastar Pharmaceuticals Inc (AMPH) gets rating Initiated from JP Morgan

Amphastar Pharmaceuticals Inc’s filing revealed that its Director Petersen Floyd F. unloaded Company’s shares for reported $21714.0 on Apr 01 ’24. In the deal valued at $43.43 per share,500 shares were sold. As a result of this transaction, Petersen Floyd F. now holds 79,333 shares worth roughly $3.27 million.

Then, PETERS WILLIAM J sold 18,136 shares, generating $842,883 in total proceeds. Upon selling the shares at $46.48, the CFO, EVP & TREASURER now owns 111,490 shares.

Before that, ZASLOFF MICHAEL A sold 12,500 shares. Amphastar Pharmaceuticals Inc shares valued at $589,724 were divested by the Director at a price of $47.18 per share. As a result of the transaction, ZASLOFF MICHAEL A now holds 21,326 shares, worth roughly $0.88 million.

JP Morgan initiated its Amphastar Pharmaceuticals Inc [AMPH] rating to an Overweight in a research note published on March 05, 2024; the price target was $60. A number of analysts have revised their coverage, including BofA Securities’s analysts, who began to cover the stock in mid November with a ‘”a Neutral”‘ rating.

Price Performance Review of AMPH

On Tuesday, Amphastar Pharmaceuticals Inc [NASDAQ:AMPH] saw its stock fall -1.83% to $41.25. Over the last five days, the stock has gained 0.83%. Amphastar Pharmaceuticals Inc shares have fallen nearly -33.31% since the year began. Nevertheless, the stocks have risen 15.32% over the past one year. While a 52-week high of $67.66 was reached on 01/05/24, a 52-week low of $35.69 was recorded on 04/18/24. SMA at 50 days reached $44.24, while 200 days put it at $51.45. A total of 0.35 million shares were traded, compared to the trading of 0.34 million shares in the previous session.

Levels Of Support And Resistance For AMPH Stock

The 24-hour chart illustrates a support level at 40.87, which if violated will result in even more drops to 40.50. On the upside, there is a resistance level at 41.96. A further resistance level may holdings at 42.68. The Relative Strength Index (RSI) on the 14-day chart is 45.89, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 0.93, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bullish at 28.24%. Stochastics %K at 82.15% indicates the stock is a selling.

The most recent change occurred on July 29, 2022 when CapitalOne began covering the stock and recommended ‘”an Overweight”‘ rating along with a $44 price target.

Most Popular

[the_ad id="945"]